US Patent

US10426780 — Antiviral therapy

Method of Use · Assigned to ViiV Healthcare Co · Expires 2031-01-24 · 5y remaining

Vulnerability score 68/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects combinations of HIV integrase inhibitors and other therapeutic agents for inhibiting HIV replication and treating HIV infection and AIDS.

USPTO Abstract

The present invention relates to combinations of compounds comprising HIV integrase inhibitors and other therapeutic agents. Such combinations are useful in the inhibition of HIV replication, the prevention and/or treatment of infection by HIV, and in the treatment of AIDS and/or ARC.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-257`	—

Patent Metadata

Patent number: US10426780
Jurisdiction: US
Classification: Method of Use
Expires: 2031-01-24
Drug substance claim: Yes
Drug product claim: Yes
Assignee: ViiV Healthcare Co
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.